BYBirsen Pinar Yildiz

Birsen Pinar Yildiz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Birsen Pinar Yildiz has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Exercise Capacity and Occupational Competence Sequelae in COVID-19 Survivors: A Longitudinal Study

    by Vildan Fidanoglu, Melda Saglam, Serkan Pekcetin, Naciye Vardar Yagli, Birsen Pinar Yildiz, Mesut Bayraktaroglu, Esra Ergun Alis

    The Sars-Cov-2 infection disease (COVID-19) causes symptoms during both acute and post-COVID phases. This study assessed exercise capacity and occupational competence of 20 hospitalized COVID-19 patients, at discharge and three months later using the 6-Minute Step Test and Occupational Self-Assessment. Significant differences were found in both exercise capacity and occupational competence scores between discharge and three months later (p < 0.05). However, these measurements were not correlated (p > 0.05). Although patients show improvement after discharge, some symptoms persisted, affecting their exercise, and occupational performance. Further research is needed to explore long-term occupational outcomes of COVID-19 beyond one year.

  • Persistent allergic rhinitis and its potential to cause poor asthma control

    by Cihan Aydin, Gülsün Çakır Odabaş, Fulya Omak Kaya, Pınar Yıldız

    Objective: Many studies have shown the worsening impact of allergic rhinitis on the management of asthma. In this study, we aimed to address the association between persistent allergic rhinitis and poor asthma control. Material and methods: This multi-center cross-sectional study was performed with the participation of patients with asthma and persistent allergic rhinitis visiting the pulmonology outpatient clinics between 01.02.2022 and 01.08.2022. The demographic data, Asthma Control Test (ACT) scores, and asthma control status of the patients were recorded. The sample was divided into two groups according to asthma control status "uncontrolled asthma" and "controlled asthma". The Score for Allergic Rhinitis (SFAR) was used to evaluate the diagnosis of allergic rhinitis (AR). Results: We included 195 patients (47 (24.1%) men and 148 (75.9%) women) with a mean age of 44.54 in this study. While 26.7% of the patients showed asthma control, 73.3% had uncontrolled asthma. The rate of persistent allergic rhinitis was found to be significantly higher in the patients with uncontrolled asthma compared to the patients with controlled asthma (p=0.012). Conclusion: This study showed that persistent allergic rhinitis has a worsening impact on asthma control. Patients with asthma and concomitant persistent allergic rhinitis should be treated and followed up considering their higher risk of poor asthma control. Those patients with persistent symptoms of rhinitis cause major problems in public health with the increased healthcare costs.

  • Open Access

    An Alpha-1 Antitrypsin Deficiency Screening Study in Patients with Chronic Obstructive Pulmonary Disease, Bronchiectasis, or Asthma in Turkey

    by Seda Tural Onur, Antonino Natoli, Bettina Dreger, Sibel Arınç, Nurhan Sarıoğlu, Mustafa Çörtük, Dilek Karadoğan, Abdurrahman Şenyiğit, Birsen Pınar Yıldız, Nurdan Köktürk, et al.

    Purpose: Alpha-1 antitrypsin deficiency (AATD) is a rare hereditary condition characterized by decreased serum alpha-1 antitrypsin (AAT) levels. We aim to identify AATD in patients with chronic obstructive pulmonary disease (COPD), bronchiectasis, or asthma and to report the frequency of AAT variants in Turkey. Patients and Methods: This non-interventional, multicenter, prospective study was conducted between October 2021 and June 2022. Adult patients with COPD, bronchiectasis, asthma, liver symptoms, or family members with AATD were included. Demographic and clinical characteristics, pulmonary diagnosis, respiratory symptoms, and AAT serum levels were assessed. Whole blood samples were collected as dried blood spots, and the most common AATD mutations were simultaneously tested by allele-specific genotyping. Results: A total of 1088 patients, mainly diagnosed with COPD (92.7%) and shortness of breath (78.7%), were assessed. Fifty-one (5%) were found to have AATD mutations. Fifteen (29.4%) patients had Pi*S or Pi*Z mutations, whereas 36 (70.6%) patients carried rare alleles Pi*M malton (n=18, 35.3% of mutations), Pi*I (n=8, 16%), Pi*P lowell (n=7, 14%), Pi*M heerlen (n=2, 4%), and Pi*S iiyama (n=1, 2%). The most common heterozygous combinations were Pi*M/Z (n=12, 24%), and Pi*M/M malton (n=11, 22%). Ten patients with severe AATD due to two deficiency alleles were identified, two with the Pi*Z/Z genotype, four with the genotype Pi*M malton/M malton, three with Pi*Z/M malton, and one with Pi*Z/M heerlen. Conclusion: Our results identified AATD mutations as a genetic-based contributor to lung disease in patients with COPD or bronchiectasis and assessed their frequency in a population of Turkish patients.


  • Open Access

    Fatigue has a prominent impact on health lasting 12-weeks after COVID-19 infection

    by Birsen Pınar Yıldız, Didem Görgün Hattatoğlu, Cihan Aydin, Gülnihal Darçın

    BackgroundWhile the amount of information on many issues related to COVID-19 has increased, the long-term consequences of illness and disability remain largely unclear. In previous studies on COVID-19 infections, long-lasting functional and symptomatic abnormalities have also been shown. It is predicted that survivors of COVID-19 may have to deal with physical or psychological problems later.Aim We aimed to evaluate long-lasting symptoms including fatigue and investigate the associated risk factors.Methods In this prospective cohort study, 132 consecutive COVID-19 patients who were previously diagnosed and admitted 13±1 weeks after diagnosis were included. The Functional Assessment of Chronic Illness Therapy (FACIT) – Fatigue Scale, the Beck Anxiety Inventory, the Beck Depression Inventory, and the Lawton Instrumental Activities of Daily Living (IADL) Scale were applied in the follow-up visit.ResultsThe median age of the patients (76 male, 56 female) was 52. Eighty (61%) of the patients were hospitalized, while 52 (39%) of them were not hospitalized. At least one symptom persisted in 103 (78%) patients, with fatigue (n=48, 36%) being the most common symptom. Both dyspnea and fatigue were more prominent in women than in men (34% vs. 11%, p=0.001 and 46% vs 29%, p=0.03; respectively). Persisted symptoms including fatigue were not significantly associated with hospitalization status. The FACIT scores of the patients at 12 weeks were positively associated with their depression and anxiety levels (R: 0.55, p=0.0001 and R: 0.42, p=0.0001), while they were negatively associated with their IADL scores (R: -0.25, p=0.004).Conclusions Fatigue was the most frequent persistent symptom. The initial fatigue scores were higher in the severely ill patients. Persistent fatigue was not associated with disease severity but was closely associated with anxiety and depression.


  • Open Access

    Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in non-small cell lung cancer

    by Mesut Bayraktaroglu, Birsen Pinar Yildiz

    Non-small cell lung cancer (NSCLC) is characterized by diagnosis at an advanced stage, low rate of operability and poor survival. Therefore, there is a need for a biomarker in NSCLC patients to predict the likely outcome and to accurately stratify the patients in terms of the most appropriate treatment modality. To evaluate prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in NSCLC. A total of 124 NSCLC patients (mean ± standard deviation age: 60.7 ± 9.3 years, 94.4% were males) were included in this retrospective study. Data were retrieved from the hospital records. The association of NLR and PLR with clinicopathological factors and overall survival was analyzed. One-year, 2-year and 5-year survival rates were 59.2%, 32.0%, and 16.2%, respectively. Median duration of survival was shorter in patient groups with elevated NLR and PLR. Five-year survival rate was quite lower in patient groups with elevated NLR and PLR. Hazard rate (HR) for mortality was 1.76 (95% confidence interval [CI]: 1.19–2.61, P = .005) for NLR ≥ 3 over NLR < 3. HR was 1.64 (95%CI: 1.11–2.42, P = .013) for PLR ≥ 150 over PLR < 150. Cox-regression analysis revealed that, when adjusted for other independent predictors of survival, NLR and PLR still remain significant predictors of poorer survival. Our findings indicate that elevated pretreatment NLR and PLR are associated with advanced disease and poor survival in NSCLC patients, NLR and PLR values are correlated with each other.


  • Open Access

    The CO-MIND Study: Chronic Obstructive Pulmonary Disease Management in Daily Practice and Its Implications for Improved Outcomes According to GOLD 2019 Perspective

    by Hakan Gunen, Nurdan Kokturk, Sibel Naycı, Sevket Ozkaya, Birsen Pınar Yıldız, Onur Turan, Aziz Gumus, Metin Akgun, Alev Gurgun, Candan Ogus, et al.

    Purpose: GOLD 2019 proposed a novel treatment decision tool for follow-up based on the predominant trait (exacerbation or dyspnea) of patients, alongside treatment escalation and de-escalation strategies. This study was designed to provide an up-to-date snapshot of patient and disease characteristics, treatment pathways, and healthcare resource use (HRU) in COPD in real life, and comprehensively examine patients considering GOLD 2019 recommendations. Patients and Methods: This mixed design, observational, multicenter (14 pulmonology clinics) study included all patients with a documented COPD diagnosis (excluding asthma-COPD overlap [ACO]) for ≥ 12 months, aged ≥ 40 years at diagnosis who had a COPD-related hospital visit, spirometry test and blood eosinophil count (BEC) measurement under stable conditions within the 12 months before enrollment between February and December 2020. Data were collected cross-sectionally from patients and retrospectively from hospital medical records. Results: This study included 522 patients (GOLD group A: 17.2%, B: 46.4%, C: 3.3%, D: 33.1%), of whom 79.5% were highly symptomatic and 36.2% had high risk of exacerbation. Exacerbations (n = 832; 46.6% moderate, 25.5% severe) were experienced by 57.5% of patients in the previous 12 months. Inter-rater agreement between investigators and patients regarding the reason for visit was low (κ coefficient: 0.338, p = 0.001). Inhaled treatment was modified in 88 patients at index, mainly due to symptomatic state (31.8%) and exacerbations (27.3%); treatment was escalated (57.9%, mainly switched to LABA+LAMA+ICS), inhaler device and/or active ingredient was changed (36.4%) or treatment was de-escalated (5.7%). 27% had ≥ 1 hospital overnight stay over 12 months. Emergency department visits and days with limitation of daily activities were higher in group D (p < 0.001). Conclusion: Despite being on-treatment, many patients with COPD experience persistent symptoms and exacerbations requiring hospital-related HRU. A treatable trait approach and holistic disease management may improve outcomes by deciding the right treatment for the right patient at the right time.


  • Open Access

    D-dimer/Fibrinogen ratio and recurrent exacerbations might have a potential impact to predict 90-day mortality in patients with COPD exacerbation

    by Cihan Aydin, Birsen Pınar Yıldız, Didem Görgün Hattatoğlu

    Background According to the World Health Organisation reports (WHO), COPD is the third leading cause of overall in the World by 2020. Aim We aimed to determine the prognostic predictors of 90-day mortality after an initial exacerbation in patients with acute exacerbation of COPD (AECOPD). Results Increased Charlson Comorbidity Score(CCS) (HR:1.47; pConclusion Our study showed that D-dimer/Fibrinogen ratio but not D-dimer and recurrent exacerbations after discharge might have a critical impact on 90-day mortality


  • Open Access

    Does smoking impair sleep hygiene?

    by Didem Görgün Hattatoğlu, Şenay Aydin, Birsen Pınar Yildiz

    Background: Sleep architecture and sleep hygiene might be disrupted by several pathogenetic mechanisms, and the effect of smoking has not been evaluated. Objective: To investigate the effect of smoking on sleep hygiene behaviors that might be associated with the deterioration of quality-of-life (QoL) parameters. Methods: In a prospective cross-sectional study, smokers (n=114) and nonsmokers (n=119) were included. The Pittsburgh Sleep Quality İndex (PSQI), the Epworth Daytime Sleepiness Scale (ESS), the Sleep Hygiene Index (SHI), and the Short Form-36 quality of life scale (SF-36) were applied. Results: We found that none of the components, as well as the PSQI total score were affected in smokers compared with the nonsmoker controls (65.5% of smokers had poor sleep compared to 62.5% of nonsmokers). Although smokers tend to get out of bed at different times from day to day and do important work before bedtime (components of the SHI) more often than non-smokers, no significant differences were detected between groups in any component and SHI total score (27.91±6.72 for smokers and 29.23±8.0 for non-smokers). ESS, depression and anxiety symptoms, and SHI scores in smokers with poor sleep quality were significantly different compared with smokers that had normal sleep quality. Both PSQI and SHI scores were inversely associated with QoL parameters. Conclusions: Our results suggest that smoking by itself is not associated with poor sleep hygiene or sleep quality. It can be concluded that worse SHI and quality of sleep negatively affect QoL, depression, and anxiety in smokers.


  • Open Access

    Management of Postoperative Complications

    by Birsen Pınar Yıldız, Mesut Bayraktaroğlu